Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-19T06:41:51.386Z Has data issue: false hasContentIssue false
  • English
  • Français

A blinded, placebo-controlled randomized trial of low-dose risperidone, intensive psychological treatment and befriending in young people at risk of psychotic disorder: baseline characteristics of the sample

Published online by Cambridge University Press:  24 June 2014

P McGorry ,
A Yung ,
S Francey ,
L Phillips  and
B Nelson
P McGorry
Affiliation:
ORYGEN Research Centre
A Yung
Affiliation:
ORYGEN Research Centre
S Francey
Affiliation:
ORYGEN Research Centre
L Phillips
Affiliation:
ORYGEN Research Centre Department of Psychology, The University of Melbourneand ORC, Melbourne, Australia
B Nelson
Affiliation:
ORYGEN Research Centre
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstracts from ‘Brainwaves’— The Australasian Society for Psychiatric Research Annual Meeting 2006, 6–8 December, Sydney, Australia
Information
Acta Neuropsychiatrica , Volume 18 , Issue 6 , December 2006 , pp. 261
Copyright
Copyright © 2006 Blackwell Munksgaard

Background:

Intervention during the prodromal phase of psychotic disorder has become an important focus of early intervention research.

Method:

The PACE Clinic, ORYGEN Youth Health, has been conducting a blinded randomized controlled trial (RCT) comparing the effectiveness of low-dose risperidone (0.5–2.0 mg/day) and intensive CBT-based psychological treatment vs. placebo and intensive CBT-based psychological treatment vs. placebo and a control psychological treatment (befriending). The trial consists of a 12-month treatment phase, followed by a 12-month follow-up phase. The primary outcome of interest is the proportion of patients meeting onset of psychosis criteria during the treatment and follow-up phases.

Results:

The current presentation will describe baseline characteristics of the sample. About 119 participants (mean age = 18.36 years, men = 41.2%) meeting ultrahigh-risk criteria for psychotic disorder were randomized to the three treatment groups. Baseline characteristics will be compared between 1) the three treatment groups and 2) the treatment groups and a monitoring group (n = 83, mean age = 18.45 years, men = 41%), who received ‘treatment as usual’.

Conclusion:

Pending.